Assessment of BRAFV600 mutant circulating cell-free tumor DNA could be a tool for therapeutic monitoring in BRAFV600 mutant metastatic melanoma patients treated with BRAF/MEK inhibitors, since a relationship has been shown between this ctDNA, durable responses, and survival outcomes [30]. The gene discussed is BRAF; the disease is metastatic melanoma.